다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Scientific reports, v.8, 2018년, pp.6412 -
Arndt, Joseph W. (Biogen, Cambridge, MA USA) , Qian, Fang (Biogen, Cambridge, MA USA) , Smith, Benjamin A. (Biogen, Cambridge, MA USA) , Quan, Chao (Biogen, Cambridge, MA USA) , Kilambi, Krishna Praneeth (Biogen, Cambridge, MA USA) , Bush, Martin W. (The Rockefeller University, New York, NY USA) , Walz, Thomas (Biogen, Cambridge, MA USA) , Pepinsky, R. Blake (Biogen, Cambridge, MA USA) , Bussière, Thierry (Biogen, Cambridge, MA USA) , Hamann, Stefan (Biogen, Cambridge, MA USA) , Cameron, Thomas O. (Biogen, Cambridge, MA USA) , Weinreb, Paul H. (Biogen, Cambridge, MA USA)
AI-Helper
Aducanumab, a human-derived antibody targeting amyloid-β (Aβ), is in Phase 3 clinical trials for the treatment of Alzheimer’s disease. Biochemical and structural analyses show that aducanumab binds a linear epitope formed by amino acids 3–7 of the Aβ peptide. Aducanumab discrim...
1. Selkoe DJ Abraham CR Podlisny MB Duffy LK Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer’s disease J Neurochem 1986 46 1820 1834 10.1111/j.1471-4159.1986.tb08501.x 3517233
2. Bayer T Wirths O Focusing the amyloid cascade hypothesis on N-truncated Aβ peptides as drug targets against Alzheimer’s disease Acta Neuropathol. 2014 127 787 801 10.1007/s00401-014-1287-x 24803226
3. Selkoe DJ Hardy J The amyloid hypothesis of Alzheimer’s disease at 25years EMBO Molecular Medicine 2016 8 595 608 10.15252/emmm.201606210 27025652
4. Polanco JC Amyloid-β and tau complexity - towards improved biomarkers and targeted therapies Nat Rev Neurol. 2018 14 22 29 10.1038/nrneurol.2017.162 29242522
5. Mullard A Alzheimer amyloid hypothesis lives on Nat Rev Drug Discov. 2016 16 3 5 10.1038/nrd.2016.281 28031570
6. Budd Haeberlein SL Harris TJ Promising targets for the treatment of neurodegenerative diseases Clin Pharmacol Ther. 2015 98 492 501 10.1002/cpt.195 26250447
7. van Dyck CH Anti-amyloid-β monoclonal antibodies for Alzheimer’s disease: pitfalls and promise Biological Psychiatry 2018 83 311 319 10.1016/j.biopsych.2017.08.010 28967385
8. Sevigny J Aducanumab removes β-amyloid plaques and slows clinical decline in Alzheimer’s disease Nature 2016 537 50 56 10.1038/nature19323 27582220
9. Bohrmann B Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β J Alzheimers Dis. 2012 28 49 69 21955818
10. Bohrmann B A comparative study of binding properties of gantenerumab and aducanumab analog to aggregated amyloid-β Neurodegener Dis. 2017 17 suppl 1 829
11. Lannfelt, L. et al . Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease. Alzheimers Res Ther . 6 , 10.1186/alzrt246 (2014).
12. Englund H Sensitive ELISA detection of amyloid-β protofibrils in biological samples J Neurochem. 2007 103 334 345 17623042
13. Gardberg AS Molecular basis for passive immunotherapy of Alzheimer’s disease Proc Natl Acad Sci USA 2007 104 15659 15664 10.1073/pnas.0705888104 17895381
14. Feinberg H Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab Alzheimer’s Res Ther. 2014 6 31 10.1186/alzrt261 25024748
15. Watt AD Do current therapeutic anti-Aβ antibodies for Alzheimer’s disease engage the target? Acta Neuropathologica 2014 127 803 810 10.1007/s00401-014-1290-2 24803227
16. Ultsch, M. et al . Structure of crenezumab complex with Aβ Shows Loss of β-Hairpin. Sci Rep . 6 , 10.1038/srep39374 (2016).
17. Adolfsson O An effector-reduced anti-β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ J Neurosci. 2012 32 9677 9689 10.1523/JNEUROSCI.4742-11.2012 22787053
18. Crespi, G. A. N., Hermans, S. J., Parker, M. W. & Miles, L. A. Molecular basis for mid-region amyloid-β capture by leading Alzheimer’s disease immunotherapies. Sci Rep . 5 , 10.1038/srep09649 (2015).
19. La Porte SL Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer’s disease J Mol Bio. 2012 421 525 536 10.1016/j.jmb.2011.11.047 22197375
20. Jarrett JT Berger EP Lansbury PT The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease Biochem. 1993 32 4693 4697 10.1021/bi00069a001 8490014
21. DeMattos RB Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer’s disease Proc Natl Acad Sci USA 2001 98 8850 8855 10.1073/pnas.151261398 11438712
22. Miles LA Crespi GA Doughty L Parker MW Bapineuzumab captures the N-terminus of the Alzheimer’s disease amyloid-β peptide in a helical conformation Sci Rep. 2013 3 1302 10.1038/srep01302 23416764
23. Raveh B London N Zimmerman L Schueler-Furman O Rosetta FlexPepDock ab-initio: simultaneous folding, docking and refinement of peptides onto their receptors PLoS ONE 2011 6 e18934 10.1371/journal.pone.0018934 21572516
24. Basi GS Structural correlates of antibodies associated with acute reversal of amyloid β-related behavioral deficits in a mouse model of Alzheimer disease J Bio Chem. 2010 285 3417 3427 10.1074/jbc.M109.045187 19923222
25. Crespi GA Ascher DB Parker MW Miles LA Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer’s disease immunotherapy candidate bapineuzumab complexed with amyloid-β Acta Crystallogr F Struct Biol Commun. 2014 70 374 377 10.1107/S2053230X14001642 24598931
26. Miles LA Amyloid-β-anti-amyloid-β complex structure reveals an extended conformation in the immunodominant B-cell epitope J Mol Biol 2008 377 181 192 10.1016/j.jmb.2007.12.036 18237744
27. Dalgediene I Immunogenic properties of amyloid β oligomers J Biomed Sci 2013 20 1 7 10.1186/1423-0127-20-10 23286586
28. Lee M Aβ42 immunization in Alzheimer’s disease generates Aβ N-terminal antibodies Ann Neurol. 2005 58 430 435 10.1002/ana.20592 16130106
29. Freir DB Aβ oligomers inhibit synapse remodelling necessary for memory consolidation Neurobiol Aging 2011 32 2211 2218 10.1016/j.neurobiolaging.2010.01.001 20097446
30. Mucke, L. & Selkoe, D. J. Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2 , 10.1101/cshperspect.a006338 (2012).
31. Reed MN Cognitive effects of cell-derived and synthetically derived Aβ oligomers Neurobiology of Aging 2011 32 1784 1794 10.1016/j.neurobiolaging.2009.11.007 20031278
32. Giuffrida ML β-amyloid monomers are neuroprotective J. Neurosci. 2009 29 10582 10587 10.1523/JNEUROSCI.1736-09.2009 19710311
33. Brannstrom, K. et al . A generic method for design of oligomer-specific antibodies. PloS One 9 , 10.1371/journal.pone.0090857 (2014).
34. Golde TE Das P Levites Y Quantitative and mechanistic studies of Aβ immunotherapy CNS Neurol Disord Drug Targets 2009 8 31 49 10.2174/187152709787601830 19275635
35. Gregory GC Halliday GM What is the dominant Aβ species in human brain tissue? A review Neurotox Res. 2005 7 29 41 10.1007/BF03033774 15639796
36. Hu WT CSF beta-amyloid 1-42 - what are we measuring in Alzheimer’s disease? Ann Clin Transl Neurol. 2015 2 131 139 10.1002/acn3.160 25750918
37. Oe T Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer’s disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry Rapid Commun Mass Spectrom 2006 20 3723 3735 10.1002/rcm.2787 17117458
38. Tucker S The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice J Alzheimer’s Dis. 2015 43 575 588 25096615
39. Benilova I Karran E De Strooper B The toxic Aβ oligomer and Alzheimer’s disease: an emperor in need of clothes Nat Neurosci. 2012 15 349 357 10.1038/nn.3028 22286176
40. Lord A An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer’s disease Neurobiol Dis. 2009 36 425 434 10.1016/j.nbd.2009.08.007 19703562
41. Kayed R Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis Science 2003 300 486 489 10.1126/science.1079469 12702875
42. Lee EB Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice J Biol Chem 2006 281 4292 4299 10.1074/jbc.M511018200 16361260
43. Morgado I Molecular basis of β-amyloid oligomer recognition with a conformational antibody fragment Proc Natl Acad Sci USA 2012 109 12503 12508 10.1073/pnas.1206433109 22814377
44. Shughrue PJ Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons Neurobiol Aging 2010 2010 189 202 10.1016/j.neurobiolaging.2008.04.003
45. Colvin BA The conformational epitope for a new Aβ42 protofibril-selective antibody partially overlaps with the peptide N-terminal region J Neurochem. 2017 143 736 749 10.1111/jnc.14211 28881033
46. Hatami A Albay R Monjazeb S Milton S Glabe C Monoclonal antibodies against Aβ42 fibrils distinguish multiple aggregation state polymorphisms in vitro and in Alzheimer disease brain J. Bio. Chem. 2014 289 32131 32143 10.1074/jbc.M114.594846 25281743
47. Tycko R Amyloid polymorphism: structural basis and neurobiological relevance Neuron 2015 86 632 645 10.1016/j.neuron.2015.03.017 25950632
48. Colvin MT Atomic resolution structure of monomorphic Aβ(42) amyloid fibrils J Amer Chem Soc. 2016 138 9663 9674 10.1021/jacs.6b05129 27355699
49. Walti MA Atomic-resolution structure of a disease-relevant Aβ(1–42) amyloid fibril Proc Natl Acad Sci USA 2016 113 E4976 E4984 10.1073/pnas.1600749113 27469165
50. Xiao YL Aβ(1–42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer’s disease Nat Struct Mol Bio. 2015 22 499 U497 10.1038/nsmb.2991 25938662
51. Lu JX Molecular structure of β-amyloid fibrils in Alzheimer’s disease brain tissue Cell 2013 154 1257 1268 10.1016/j.cell.2013.08.035 24034249
52. Paravastu AK Qahwash I Leapman RD Meredith SC Tycko R Seeded growth of β-amyloid fibrils from Alzheimer’s brain-derived fibrils produces a distinct fibril structure Proc Natl Acad Sci USA 2009 106 7443 7448 10.1073/pnas.0812033106 19376973
53. Qiang W Yau WM Lu JX Collinge J Tycko R Structural variation in amyloid- β fibrils from Alzheimer’s disease clinical subtypes Nature 2017 541 217 221 10.1038/nature20814 28052060
54. Bard F Peripherally administered antibodies against amyloid β peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 919 10.1038/78682 10932230
55. Petkova AT Self-propagating, molecular-level polymorphism in Alzheimer’s β-amyloid fibrils Science 2005 307 262 265 10.1126/science.1105850 15653506
56. Lusty CJ A gentle vapor-diffusion technique for cross-linking of protein crystals for cryocrystallography J Appl Cryst. 1999 32 106 112 10.1107/S002188989801053X
57. Otwinowski Z Minor W Processing of X-ray diffraction data collected in oscillation mode Methods Enzymol. 1997 276 307 326 10.1016/S0076-6879(97)76066-X
58. Winn MD Overview of the CCP4 suite and current developments Acta Crystallogr D Biol Crystallogr. 2011 67 235 242 10.1107/S0907444910045749 21460441
59. Emsley P Lohkamp B Scott WG Cowtan K Features and development of Coot Acta Crystallogr D Biol Crystallogr. 2010 66 486 501 10.1107/S0907444910007493 20383002
60. Vagin AA REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use Acta Crystallogr D Biol Crystallogr. 2004 60 2184 2195 10.1107/S0907444904023510 15572771
61. Krissinel E Henrick K Inference of macromolecular assemblies from crystalline state J Mol Bio. 2007 372 774 797 10.1016/j.jmb.2007.05.022 17681537
62. Lawrence MC Colman PM Shape complementarity at protein/protein interfaces J Mol Bio. 1993 234 946 950 10.1006/jmbi.1993.1648 8263940
63. Leaver-Fay A Al. E ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules Methods Enzymol. 2011 487 545 574 10.1016/B978-0-12-381270-4.00019-6 21187238
64. Bradley P Misura KMS Baker D Toward high-resolution de novo structure prediction for small proteins Science 2005 309 1868 1871 10.1126/science.1113801 16166519
65. Kilambi KP Reddy K Gray JJ Protein-protein docking with dynamic residue protonation states PLoS Comput Biol 2014 10 e1004018 10.1371/journal.pcbi.1004018 25501663
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.